MBChB, MRCP, PhD
University Research Lecturer
- British Heart Foundation Intermediate Clinical Research Fellow
My work focuses on understanding how obesity leads to the development of diabetes and cardiovascular disease. In particular, my research aims to understand how a family of growth factors, known as Wnts regulates adipocyte number (adipose tissue 'expandability') and distribution within the body; two key determinants of susceptibility to obesity-associated cardiometabolic disease. In order to achieve this we employ human genetic and physiological approaches, accompanied by functional studies in human fat depot-specific cellular models. Recently we identified a key Wnt receptor, LRP5, as a novel human fat distribution gene.
Of interest LRP5 is a current drug target for the treatment of osteoporosis illustrating the translational potential of the research. In the longer term we hope to exploit our findings to develop novel therapies for obesity and cardiometabolic diseases.
I am currently a BHF Intermediate Clinical Research Fellow and Honorary Consultant in Endocrinology and Diabetes. Prior to this I competed my PhD at the University of Cambridge before taking up an Academic Clinical Lecturer post at the University of Oxford.
LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion.
Loh NY. et al, (2015), Cell Metab, 21, 262 - 273
Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas.
Capatina C. et al, (2013), Clin Endocrinol (Oxf), 78, 86 - 93
Wnt signaling in cardiovascular physiology
Marinou K. et al, (2012), Trends in Endocrinology and Metabolism, 23, 628 - 636
Wnt signaling in cardiovascular physiology.
Marinou K. et al, (2012), Trends Endocrinol Metab, 23, 628 - 636
The role of adiponectin in human vascular physiology.
Vaiopoulos AG. et al, (2012), Int J Cardiol, 155, 188 - 193